glp 1 agonist muscle loss Weight with GLP-1 medicines does not result in a disproportionate loss of mass or function in obese mice and humans: Cell Reports Medicine Future questions for GLP1 receptor
Description
The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update

Neuropsychiatry Clin

Creutzfeldt, W
doi: 10.1001/jamacardio.2020.1966 136 AlorfiNMAlgarniAS
